explore -WSS

explore

author：fashion 2025-10-02 00:39:54 - browse：9978

President Biden speaks on the Cancer Moonshot initiative at the John F. Kennedy Library in 2022. Evan Vucci/AP

WASHINGTON — The next chapter of President Biden’s moonshot to end cancer has landed. While the new goals are inspiring hope among cancer researchers, not everyone is impressed.

The president early Wednesday morning unveiled a slew of federal plans and private-sector agreements to fuel the relaunched Cancer Moonshot, a project to improve treatments and halve cancer deaths in the next 25 years. Among roughly 50 new programs and partnerships are multimillion-dollar pledges to advance testing, data pools, clinical trials and outreach efforts.

It is the latest phase of a project Biden first launched as vice president in the wake of his son Beau’s death from brain cancer in 2015. But while the first moonshot funneled money almost entirely to early-stage cancer research, its sequel is broadening efforts to prevent cancer deaths — particularly through anti-smoking efforts — and introduces a new focus on research infrastructure and patient engagement that some cancer researchers have applauded.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Novavax promises a turnaround & Lilly roils the obesity market
Next article： Physician subsidies by hospitals soar in wake of No Surprises Act

WSS

Meta's Zuckerberg and Chan on track to put $50 billion into science

PhRMA lawsuit over Medicare drug price negotiation tossed

Robert F. Kennedy is pitching centrism on health, even on abortion

Senators start work on Medicare physician payment reform

Eli Lilly to pay $200M for Beam’s stake in gene

Senate panel to vote on hospitals, PBMs, prisoner care

focus

explore

knowledge

Medicare proposal to cover medical devices draws a mixed reaction

Biden's order seeks to regulate AI risk without stifling innovation

Wildfire smoke exposes gaps in outdoor worker protections

Readout Newsletter: New research from Sanofi, Regeneron, etc.

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Eli Lilly to pay $200M for Beam’s stake in gene

Novavax promises a turnaround & Lilly roils the obesity market

Industry veterans launch new biotech VC with $310M

Affirmative action in medical school literally saved lives

Senate panel to vote on hospitals, PBMs, prisoner care

explore

Medtronic CEO on promising devices for diabetes, hypertension

Gilead might be held responsible for not developing a drug

'Revelatory' study finds a smoking impact that remains after quitting

What should King Charles tell the public about his cancer?

CDC recommends rationing of RSV shot due to shortages

Why Sanofi got shellacked over its spinoff

hotspot

Wikipedia

focus

explore